Get the Stockscreener App
18.45
1.60%
0.29
Arrivent Biopharma Inc stock is traded at $18.45, with a volume of 270.91K.
It is up +1.60% in the last 24 hours and down -3.50% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$18.16
Open:
$18.35
24h Volume:
270.91K
Relative Volume:
0.85
Market Cap:
$748.50M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-4.5896
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
+0.99%
1M Performance:
-3.50%
6M Performance:
-0.22%
1Y Performance:
-21.49%
1-Day Range:
$18.10
$18.69
1-Week Range:
$17.04
$18.79
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
18.45 | 736.73M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Is it too late to sell ArriVent BioPharma Inc.Risk Management & Low Risk High Win Rate Picks - newser.com
Will ArriVent BioPharma Inc. stock see PE expansion2025 Market Outlook & Weekly High Momentum Picks - newser.com
Is ArriVent BioPharma Inc. stock attractive after correctionJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Market Summary & Stock Market Timing Techniques - newser.com
How moving averages guide ArriVent BioPharma Inc. tradingTrade Analysis Summary & AI Optimized Trade Strategies - newser.com
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN
Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com
Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com
ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria
ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz
ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks
Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener
ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener
ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times
Oncology Biotech ArriVent BioPharma Taps 25-Year Industry Veteran to Lead Lung Cancer Drug Launch - Stock Titan
Will earnings trigger a reversal in ArriVent BioPharma Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Institutional scanner results for Baker Hughes CompanyTrade Signal Summary & Daily Technical Forecast Reports - newser.com
Is ArriVent BioPharma Inc. forming a bottoming baseWeekly Trend Report & Consistent Income Trade Ideas - newser.com
Is ArriVent BioPharma Inc. stock ready for a breakoutPortfolio Profit Report & Free Community Consensus Stock Picks - newser.com
How to track smart money flows in ArriVent BioPharma Inc.Weekly Stock Summary & High Conviction Buy Zone Picks - newser.com
Resistance Check: What is the long term forecast for HP Inc stockJuly 2025 Rallies & Entry Point Strategy Guides - خودرو بانک
Quarterly Earnings: What is the cash position of ArriVent BioPharma IncJuly 2025 PostEarnings & Free Fast Gain Swing Trade Alerts - خودرو بانک
Chart based exit strategy for ArriVent BioPharma Inc.Trade Analysis Summary & Short-Term High Return Strategies - newser.com
Aug Swings: How do insiders feel about ArriVent BioPharma Inc2025 Biggest Moves & AI Forecast Swing Trade Picks - خودرو بانک
Aug Retail: Can Aris Mining Corporation be the next market leaderPortfolio Performance Summary & Real-Time Stock Price Movement Reports - khodrobank.com
Aug Setups: Will Outdoor Holding Company stock recover after earnings2025 Analyst Calls & Community Consensus Trade Alerts - khodrobank.com
NiKang Therapeutics Advances First-in-Class CDK2/4 Dual Degrader in Phase 1 Study - MyChesCo
Has ArriVent BioPharma Inc. found a price floorJuly 2025 Update & Accurate Technical Buy Alerts - newser.com
Breakout Watch: Is China Automotive Systems Inc stock heavily shorted2025 Performance Recap & Breakout Confirmation Trade Signals - خودرو بانک
Is ArriVent BioPharma Inc. building a consolidation baseEarnings Beat & Stepwise Trade Signal Implementation - newser.com
Update Report: Will ArriVent BioPharma Inc. benefit from AI trends2025 Key Highlights & Verified Swing Trading Watchlist - khodrobank.com
Breakout Watch: Does ArriVent BioPharma Inc stock have upside surprise potentialWeekly Volume Report & Precise Swing Trade Entry Alerts - khodrobank.com
Day Trade: Is ArriVent BioPharma Inc showing insider buyingJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - خودرو بانک
Wall Street Recap: Whats the profit margin of ArriVent BioPharma IncWeekly Trading Summary & Stepwise Entry and Exit Trade Signals - خودرو بانک
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):